~~U.S.~~UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

~~WASHINGTON, D.C. 20549~~_________________

~~Form~~FORM 8-K

~~Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934~~_________________

~~Date~~CURRENT ~~of Report (Date of earliest event reported):~~REPORT

~~April~~Pursuant 2,to ~~2013~~Section 13 or 15(d) of the Securities Exchange Act of 1934

~~CORTRONIX~~Date ~~BIOMEDICAL~~of ~~ADVANCEMENT~~Report ~~TECHNOLOGIES~~(Date ~~INC.~~of earliest event reported): September 29, 2014

~~(Exact name of small business issuer as specified in its charter)~~_______________________________

Nevada		000-53700		98-0515701
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer ID No.)

Cortronix Biomedical Advancement Technologies, Inc.

~~8200~~(Exact ~~N.W~~name ~~41st~~of ~~Street,~~registrant ~~Suite~~as ~~145B,~~specified in ~~Doral,~~its ~~FL 33166 (Address of principal executive offices~~charter)

~~786-859-3585 (Issuer's Telephone Number)~~_______________________________

Nevada	000-53700	98-0515701
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

8200 N.W. 41st Street, Suite 145B, Doral, FL 33166

(Address of Principal Executive Offices) (Zip Code)

(786) 859-3585
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~SECTION ~~4.01 Change~~5 in- CORPORATE ~~Registrant’s~~GOVERNANCE ~~Certifying~~AND ~~Accountant~~MANAGEMENT

OnItem ~~April~~5.02 2,Departure ~~2013~~of ~~the~~Directors ~~relationship~~or ~~between~~Certain ~~our~~Officers; ~~Company~~Election ~~and~~of ~~the~~Directors; ~~firm~~Appointment of ~~Borgers~~Certain &Officers; ~~Cutler~~Compensatory ~~CPA’s~~Arrangements ~~PLLC (“B&C”), our independent accountant changed. B&C was dismissed due to the dissolution~~ of ~~B&C.~~Certain B&C was retained to audit our financial statements as our auditors on January 10, 2013, they have not yet audited any fiscal year end, they reviewed our financial statements for the interim period ended November 30, 2012 as filed with the SEC on January 22, 2013Officers.

InResignation ~~connection with the review~~ of our financial statements for the interim period, there were no disagreements with B&C on any matter of accounting principles or practices, financial statement disclosure, or auditing scope of procedures, which disagreements, if not resolved to the satisfaction of B&C, would have caused them to make reference in connection with its reports to the subject matter of the disagreements. None of the “reportable events” described in Item 304Officer(~~a)(1)(iv) of Regulation S-K of the SEC’~~s ~~rules and regulations have occurred during the interim periods preceding the dismissal of B&C.~~)

WeEffective ~~have~~September ~~requested~~30, ~~that~~2014, ~~B&C~~Mr. ~~furnish~~Yoel Palomino usresigned ~~with~~as athe ~~letter~~President, ~~addressed~~Chief toExecutive ~~the~~Officer, ~~Commission~~Chief ~~stating~~Financial ~~whether~~Officer, itSecretary ~~agrees~~and ~~with~~Treasurer ~~the~~of ~~above~~Cortronix ~~statements.~~Biomedical Advancement ATechnologies, ~~copy~~Inc. of(the ~~this~~“Company”). ~~letter~~Mr. isJorge ~~included~~Saer ~~herewith~~resigned as ~~Exhibit~~the 16Companies Chief Technology Officer.1.

InAppointment ~~addition, effective April 2, 2013, we approved the appointment~~ of BF Borgers CPA PC (“Borgers PC”), as the Company’s independent registered public accountant, to audit our financial statement for our fiscal year ending August 31, 2013, and the interim periods therein. This change in independent accountants was approved by our Board of Directors. There were no consultations between us and Borgers PC prior to their appointment.Officer

~~Item~~Effective upon 9Mr.01 Palomino’s resignation, the Board of Directors of the Company (the “Board”) appointed Mr. Richard A. Hull to serve as the Company’s President, Chief Executive Officer, Chief Financial ~~Statements~~Officer, Secretary and ~~Exhibits~~Treasurer. Richard Hull has over 25 years of experience working with public companies. He is the founder and Managing Member of Maplehurst Investment Group, LLC a Miami Based Investment Company. Prior to founding Maplehurst, Mr. Hull was the Chief Operating Officer of Defiance Capital, LLC a Hedge Fund Manager based in New York City.

Mr. Hull currently holds no other positions with the Company. There is no arrangement or understanding pursuant to which Mr. Hull was appointed as the President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of the Company. Mr. Hull has no family relationships with any other executive officers or directors of the Company or persons nominated or chosen by the Company to become directors or executive officers. There is no material plan, contract or arrangement (cwhether or not written) to which Mr. ~~Exhibits~~Hull is a party or in which he participates that is entered into or material amendment in connection with the Company’s appointment of Mr. Hull, or any grant or award to Mr. Hull or modification thereto, under any such plan, contract or arrangement in connection with the Company’s appointment of Mr. Hull. Furthermore, the Company is not aware of any transaction requiring disclosure under Item 404(a) of Regulation S-K.

Number		Exhibit
16.1		Letter from Borgers & Cutler CPA’s PLLC

Appointment of Directors

~~SIGNATURES~~Effective September 30, 2014, the Board appointed Mr. Hull as a member of the Board. There is no arrangement or understanding pursuant to which Mr. Hull was appointed as a director of the Company. It is contemplated that Mr. Hull may serve on certain committees of the Board, but no such committee appointments have been made at this time. There is no material plan, contract or arrangement (whether or not written) to which Mr. Hull is a party or in which he participates that is entered into or material amendment in connection with the Company’s appointment of Mr. Hull, or any grant or award to Mr. Hull or modification thereto, under any such plan, contract or arrangement in connection with the Company’s appointment of Mr. Hull. Furthermore, the Company is not aware of any transaction requiring disclosure under Item 404(a) of Regulation S-K. Mr. Hull’s professional history is noted above.

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this amended report to be signed on its behalf by the undersigned hereunto duly authorized.~~SIGNATURE

	CORTRONIX BIOMEDICAL ADVANCEMENT TECHNOLOGIES INC.
Date: April 2, 2013	By:	/s/ Yoel Palomino
	Name:	Yoel Palomino
	Title:	President, Secretary, Treasurer and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Cortronix Biomedical Advancement Technologies, Inc.

	By:		/s/ Richard Hull
	Name:		Richard Hull
	Title:		Chief Executive Officer, President, Secretary and Treasurer and Director

Date: September 30, 2014

Filing Compare · Cortronix Biomedical Advancement Technologies Inc.